Akbar Mohammad J, Lukasewicz Ferreira Pâmela C, Giorgetti Melania, Stokes Leanne, Morris Christopher J
School of Pharmacy, University of East Anglia, Norwich, UK.
Beilstein J Nanotechnol. 2019 Dec 19;10:2553-2562. doi: 10.3762/bjnano.10.246. eCollection 2019.
Gastrin-releasing peptide is a member of the bombesin family of peptides. Its cognate receptor, gastrin releasing peptide receptor (GRPR), is widely expressed in cancers of the lung, pancreas and ovaries. Gastrin releasing peptide (GRP) is an autocrine growth factor in small cell lung cancer, which has very poor patient outcomes. High affinity antagonist peptides have been developed for in vivo cancer imaging. In this report we decorated pegylated liposomes with a GRPR antagonist peptide and studied its interaction with, and accumulation within, lung cancer cells. An N-terminally cysteine modified GRPR antagonist (termed cystabn) was synthesised and shown to inhibit cell growth in vitro. Cystabn was used to prepare a targeted 1,2-distearoyl--glycero-3-phosphoethanolamine--[amino(polyethylene glycol)-2000] (DSPE-PEG2000) lipid conjugate that was formulated into liposomes. The liposomes displayed desirable colloidal properties and good stability under storage conditions. Flow cytometric and microscopic studies showed that fluorescently labelled cystabn-decorated liposomes accumulated more extensively in GRPR over-expressing cells than matched liposomes that contained no cystabn targeting motif. The use of GRPR antagonistic peptides for nanoparticle targeting has potential for enhancing drug accumulation in resistant cancer cells.
胃泌素释放肽是蛙皮素肽家族的成员。其同源受体,即胃泌素释放肽受体(GRPR),在肺癌、胰腺癌和卵巢癌中广泛表达。胃泌素释放肽(GRP)是小细胞肺癌中的一种自分泌生长因子,这类患者的预后非常差。已经开发出高亲和力拮抗剂肽用于体内癌症成像。在本报告中,我们用GRPR拮抗剂肽修饰聚乙二醇化脂质体,并研究其与肺癌细胞的相互作用以及在肺癌细胞内的积累情况。合成了一种N端半胱氨酸修饰的GRPR拮抗剂(称为cystabn),并证明其在体外可抑制细胞生长。使用cystabn制备了靶向1,2 - 二硬脂酰 - sn -甘油 - 3 - 磷酸乙醇胺 - [氨基(聚乙二醇)- 2000](DSPE - PEG2000)脂质缀合物,并将其制成脂质体。这些脂质体在储存条件下表现出理想的胶体性质和良好的稳定性。流式细胞术和显微镜研究表明,与不含cystabn靶向基序的对照脂质体相比,荧光标记的cystabn修饰脂质体在GRPR过表达细胞中的积累更为广泛。使用GRPR拮抗肽进行纳米颗粒靶向具有增强耐药癌细胞中药物积累的潜力。